Clinical Trials Browser

Phase 1/2 × Unknown × Clinical Trials, Phase I as Topic × Clear all

NCT05429905 2023-03-09

Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia

Phase 1/2 Unknown

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03636685 2018-08-17

Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC

Phase 1/2 Unknown

Adenocarcinoma, Carcinoma, Squamous Cell